Mechanisms of antiphospholipid-induced thrombosis: Effects on the protein C system

Current Rheumatology Reports

Volumn 11, Issue 1, 2009, Pages 77-81

  Wahl, Denis ^a   Membre, Aurélie ^a   Perret Guillaume, Christine ^a   Regnault, Véronique ^a   Lecompte, Thomas ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 5A; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTHROMBIN ANTIBODY; BETA2 GLYCOPROTEIN 1; PROTEIN C; PROTHROMBIN;

ANTIGEN ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING; BLOOD CLOTTING TEST; COMPETITIVE INHIBITION; ENZYME ACTIVE SITE; HUMAN; HYPERCOAGULABILITY; IMMUNOPATHOLOGY; LABORATORY TEST; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; REVIEW; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; THROMBOSIS; VENOUS THROMBOEMBOLISM; ACTIVATED PROTEIN C RESISTANCE; IMMUNOLOGY; METHODOLOGY; PATHOPHYSIOLOGY; PROTEIN BINDING; THROMBOELASTOGRAPHY; THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; HUMANS; PROTEIN BINDING; PROTEIN C; PROTHROMBIN; THROMBELASTOGRAPHY; THROMBOEMBOLISM;

EID: 63449133395     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-009-0011-7     Document Type: Review

References (32)

1. Miyakis S, Lockshin MD, Atsumi T, et al.: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
2. Galli M, Reber G, de Moerloose P, de Groot PG: Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008, 6:399-401.
3. Wahl D, Thiebaugeorges O, Regnault V, et al.: Pursuing the debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008, 6:1433-1435.
4. De Laat B, Mertens K, de Groot PG: Mechanisms of disease: antiphospholipid antibodies - from clinical association to pathological mechanism. Nat Clin Pract Rheumatol 2008, 4:192-199.
5. Esmon NL, Safa O, Smirnov MD, Esmon CT: Antiphospholipid antibodies and the protein C pathway. J Autoimmun 2000, 15:221-225.
6. Oosting JD, Derksen RH, Bobbink IW, et al.: Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: An explanation for their pathogenic mechanism? Blood 1993, 81:2618-2625.
7. Smirnov MD, Triplett DT, Comp PC, et al.: On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995, 95:309-316.
8. Malia RG, Kitchen S, Greaves M, Preston FE: Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990, 76:101-107.
9. Borrell M, Sala N, de Castellarnau C, et al.: Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 1992, 68:268-272.
10. Matsuda J, Gohchi K, Kawasugi K, et al.: Inhibitory activity of anti-β2-GP I antibody on factor Va degradation by activatedprotein C and its cofactor protein S. Am J Hematol 1995, 49:89-91.
11. Hwang KK, Grossman JM, Visvanathan S, et al.: Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 2001, 167:7192-7198.
12. Simmelink MJ, Horbach DA, Derksen RH, et al.: Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br J Haematol 2001, 113:621-629.
13. Lecompte T, Wahl D, Perret-Guillaume C, et al.: Hypercoagulability resulting from opposite effects of lupus anticoagulants is predictive of thrombotic risk. Haematologica 2007, 92:714-715.
14. Hemker HC, Giesen P, Al Dieri R, et al.: Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003, 33:4-15.
15. Hemker HC, Al Dieri R, Béguin S: Thrombin generation assays: accruing clinical relevance. Curr Opin Hematol 2004, 11:170-175.
16. Regnault V, Hemker HC, Wahl D, Lecompte T: Phenotyping the haemostatic system by thrombography - potential for the estimation of thrombotic risk. Thromb Res 2004, 114:539-545.
17. Lin WS, Chen PC, Yang CD, et al.: Some antiphospholipid antibodies recognize conformational epitopes shared by b2-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum 2007, 56:1638-1647.
18. de Laat B, Eckmann CM, van Schagen M, et al.: Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C. Blood Coagul Fibrinolysis 2008, 19:757-764.
19. Membre A, Wahl D, Latger-Cannard V, et al.: The effect of platelet activation on the hypercoagulability induced by murine monoclonal antiphospholipid antibodies. Haematologica 2008, 93:566-573.
20. Male C, Mitchell L, Julian J, et al.: Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2001, 97:844-849.
21. Nojima J, Kuratsune H, Suehisa E, et al.: Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 2002, 118:577-583.
22. Brouwer JL, Bijl M, Veeger NJ, et al.: The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004, 104:143-148.
23. Kassis J, Neville C, Rauch J, et al.: Antiphospholipid antibodies and thrombosis: Association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis. Thromb Haemost 2004, 92:1312-1319.
24. Halbmayer WM, Haushofer A, Schon R, Fischer M: Influence of lupus anticoagulant on a commercially available kit for APC resistance. Thromb Haemost 1994, 72:645-646.
25. Aznar J, Villa P, Espana F, et al.: Activated protein C resistance phenotype in patients with antiphospholipid antibodies. J Lab Clin Med 1997, 130:202-208.
26. Gardiner C, Cohen H, Jenkins A, et al.: Detection of acquired resistance to activated protein C associated with antiphospholipid antibodies using a novel clotting assay. Blood Coagul Fibrinolysis 2006, 17:477-483.
27. Liestol S, Sandset PM, Mowinckel MC, Wisloff F: Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. J Thromb Haemost 2007, 5:2204-2210.
28. Wahl DG, Guillemin F, De Maistre E, et al.: Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus. A meta-analysis. Lupus 1997, 6:467-473.
29. Horbach DA, van Oort E, Donders RC, et al.: Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996, 76:916-924.
30. Wahl D, de Maistre E, Guillemin F, et al.: The risk of recurrent venous thromboembolism associated with phospholipid and patients without systemic lupus erythematosus. Q J Med 1998, 91:125-130.
31. Regnault V, Béguin S, Wahl D, et al.: Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants. Thromb Haemost 2003, 89:208-212.
32. Dargaud Y, Luddington R, Gray E, et al.: Effect of standardization and normalization on imprecision of calibrated automated thrombography: An international multicentre study. Br J Haematol 2007, 39:303-309.